Canopy Growth (NASDAQ:CGC) Releases Earnings Results, Misses Expectations By $0.11 EPS

Posted by Francis Steltz on Jun 17th, 2026

Canopy Growth (NASDAQ:CGC – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.11), Zacks reports. Canopy Growth had a negative net margin of 75.27% and a negative return on equity of 27.34%. The business had revenue of $51.22 million for the quarter, compared to analyst estimates of $53.43 million.

Here are the key takeaways from Canopy Growth’s conference call:

Canopy Growth said fiscal 2026 marked a turning point, with Canada adult-use revenue up 20%, Canada medical up 18%, and international cannabis gaining momentum. Management emphasized that cost restructuring and a recapitalization strengthened the business and extended debt maturities to 2031.
The MTL Cannabis acquisition was highlighted as a major strategic win, making Canopy the leading Canadian medical cannabis business by revenue. The company said it has already achieved CAD 6 million of its CAD 10 million annualized synergy target and expects further benefits from integration.
Fourth-quarter cannabis gross margin was pressured by CAD 10.7 million of acquisition-related inventory charges, but management said adjusted gross margin would have been 26% versus 12% a year ago. Canopy also reiterated confidence in reaching positive adjusted EBITDA during fiscal 2027.
Canadian medical growth is expected to face headwinds from Veterans Affairs reimbursement changes, and management said the business may not maintain the same growth rate seen in fiscal 2026. The company is trying to offset the impact through pricing, mix changes, and patient retention efforts.
Management struck an optimistic tone on international growth, especially Europe, citing strong sequential improvement and 68% year-over-year Q4 international revenue growth. It also said Canopy is targeting expansion into the U.K. and believes its Germany and Poland operations are well positioned.

Canopy Growth Stock Down 2.5%

Shares of Canopy Growth stock opened at $0.96 on Wednesday. Canopy Growth has a 1-year low of $0.84 and a 1-year high of $2.38. The company has a market capitalization of $387.15 million, a P/E ratio of -1.62 and a beta of 0.77. The business’s fifty day moving average price is $1.08 and its two-hundred day moving average price is $1.13. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.34 and a quick ratio of 4.26.

Trending Headlines about Canopy Growth

Here are the key news stories impacting Canopy Growth this week:

Positive Sentiment: Canopy Growth said its fiscal 2026 reset, integration of MTL Cannabis, and growth in medical cannabis could improve margins and help the company reach positive adjusted EBITDA in fiscal 2027. CGC Q4 Earnings Call Focuses on EBITDA Path
Positive Sentiment: The company reported double-digit full-year revenue growth and a narrower quarterly loss, suggesting its restructuring efforts are starting to show some progress. Canopy Growth revenue climbs 14% in Q4
Neutral Sentiment: Analysts and commentators are debating the long-term outlook, with some saying the stock may have already priced in potential cannabis policy benefits and that Canopy is still a risky turnaround story. Canopy Growth Bought Time, Not A Higher Rating
Negative Sentiment: The latest quarter also came with a revenue miss and an adjusted loss that was worse than Wall Street expected, reinforcing concerns that profitability is still far away. Canopy Growth Corporation (CGC) Reports Q4 Loss, Lags Revenue Estimates

Hedge Funds Weigh In On Canopy Growth

A number of hedge funds have recently modified their holdings of the stock. Two Sigma Securities LLC grew its holdings in shares of Canopy Growth by 4.4% in the 2nd quarter. Two Sigma Securities LLC now owns 280,852 shares of the company’s stock worth $343,000 after acquiring an additional 11,942 shares during the last quarter. Commonwealth Equity Services LLC boosted its position in shares of Canopy Growth by 23.1% in the fourth quarter. Commonwealth Equity Services LLC now owns 73,739 shares of the company’s stock worth $84,000 after buying an additional 13,814 shares during the period. Boothbay Fund Management LLC acquired a new stake in shares of Canopy Growth in the second quarter worth $30,000. Mackenzie Financial Corp boosted its position in shares of Canopy Growth by 33.1% in the third quarter. Mackenzie Financial Corp now owns 111,945 shares of the company’s stock worth $163,000 after buying an additional 27,823 shares during the period. Finally, Osaic Holdings Inc. boosted its position in shares of Canopy Growth by 77.6% in the second quarter. Osaic Holdings Inc. now owns 75,335 shares of the company’s stock worth $92,000 after buying an additional 32,927 shares during the period. 3.33% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

CGC has been the subject of a number of recent analyst reports. ATB Cormark Capital Markets upgraded Canopy Growth from a “strong sell” rating to a “moderate buy” rating in a research note on Tuesday, March 17th. Canaccord Genuity Group began coverage on Canopy Growth in a report on Friday, March 27th. They set a “buy” rating on the stock. Weiss Ratings downgraded Canopy Growth from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday. Finally, Wall Street Zen downgraded Canopy Growth from a “hold” rating to a “sell” rating in a report on Sunday, March 29th. Two equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold”.

Read Our Latest Stock Analysis on Canopy Growth

Canopy Growth Company Profile

(Get Free Report)

Canopy Growth Corporation is a leading Canadian cannabis company engaged in the production, distribution and sale of both medical and recreational cannabis products. Headquartered in Smiths Falls, Ontario, the company cultivates a diversified portfolio of offerings that includes dried flower, pre-rolled joints, oils, softgel capsules and edibles. Canopy Growth also markets derivative products such as beverages and wellness formulations under a range of brands, aiming to serve both patient and adult-use markets.

The company operates through multiple subsidiaries, including Tweed Inc, Spectrum Therapeutics and Tokyo Smoke, each targeting distinct consumer segments.